Results of a phase 3 clinical trial show an experimental drug called tolebrutinib can delay disability in patients with non-relapsing secondary progressive multiple sclerosis.
We combine professionalism, state of the art knowledge and friendliness to assure that you will receive superb service in a timely manner.
2025 © All Rights Reserved. Privacy Policy